Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

157.05
+0.63000.40%
Post-market: 157.790.7379+0.47%16:32 EST
Volume:2.43M
Turnover:380.64M
Market Cap:299.65B
PE:21.97
High:157.57
Open:156.98
Low:155.94
Close:156.42
52wk High:157.57
52wk Low:97.72
Shares:1.91B
Float Shares:1.82B
Volume Ratio:0.72
T/O Rate:0.13%
Dividend:3.99
Dividend Rate:2.54%
EPS(TTM):7.15
EPS(LYR):7.15
ROE:30.81%
ROA:11.14%
PB:6.50
PE(LYR):21.97

Loading ...

Novartis breaks ground on biomedical research center in San Diego

TIPRANKS
·
Feb 07

Blood Tests and Better-for-You Soda: Super Bowl Ads May Be Healthiest Yet -- WSJ

Dow Jones
·
Feb 06

Novartis Submits Application in China for Groundbreaking Autoimmune Drug

Stock News
·
Feb 06

Novartis price target lowered to CHF 132 from CHF 133 at Citi

TIPRANKS
·
Feb 06

Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value

TIPRANKS
·
Feb 05

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead

Benzinga
·
Feb 05

Novartis reports Q4 core EPS $2.03 vs. $1.98 last year

TIPRANKS
·
Feb 04

Dow Jones Top Company Headlines at 7 AM ET: Wegovy Maker Novo Nordisk's Shares Slump After Guidance Disappoints | GE ...

Dow Jones
·
Feb 04

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update

Dow Jones
·
Feb 04

Novartis 2026 Guidance a Bit Soft on Earnings -- Market Talk

Dow Jones
·
Feb 04

Generic Drug Competition Intensifies, Novartis Forecasts 2026 Profit Decline

Stock News
·
Feb 04

Novartis Expects Low Single-Digit Decline in 2026 Operating Profit

Reuters
·
Feb 04

Novartis Q4 Adj. EPS $1.26 Misses $1.99 Estimate, Sales $13.336B Miss $13.781B Estimate

Benzinga
·
Feb 04

Novartis Guidance in Focus as Drug Patent Losses Loom -- Earnings Preview

Dow Jones
·
Feb 03

Novartis AG Rises Friday

Dow Jones
·
Jan 31

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Jan 30

Novartis (NVS.US) siRNA Therapy "Inclisiran" Approved for New Indication

Stock News
·
Jan 28

Medicare is about to start negotiating the prices of medications administered by doctors

Dow Jones
·
Jan 28

Earning Preview: Novartis AG Q4 revenue is expected to increase by 5.72%, and institutional views lean positive

Earnings Agent
·
Jan 28

BRIEF-CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program

Reuters
·
Jan 28